SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01352637

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer

The purpose of this study is to test the differences between four active treatment conditions for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to examine predictors for PTSD and response to treatment in active duty military personnel, veterans, and civilians who served in Iraq and Afghanistan.

NCT01352637 Post Traumatic Stress Disorder
MeSH: Stress Disorders, Traumatic Stress Disorders, Post-Traumatic

4 Interventions

Name: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure

Description: 50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure

Type: Drug

DCS + Prolonged Imaginal Exposure

Name: DCS (D-Cycloserine ) + Virtual Reality Exposure

Description: 50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure

Type: Drug

DCS+VR exposure

Name: Placebo + Prolonged Imaginal Exposure

Description: Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure

Type: Drug

Placebo + Prolonged Imaginal E Placebo + Prolonged Imaginal Exposure

Name: Placebo (sugar pill) + Virtual Reality Exposure

Description: Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure

Type: Drug

Placebo + VR exposure


Primary Outcomes

Description: Clinician Administered PTSD Scale (CAPS) for the DSM-IV [34]. The CAPS-IV is a structured clinical interview designed to assess the 17 DSM-IV PTSD symptoms. CAPS-IV provides categorical ratings of diagnostic status as well as a quantitative index of symptom severity. The CAPS total severity score is based on response to the 17 items that assess the frequency and intensity of current PTSD symptoms. Symptom severity is assessed separately for past month and past week time frames. CAPS-IV range is 0-136, higher scores mean a worse outcome.

Measure: CAPS-IV at the End of Treatment

Time: after weekly treatment session 9 (at posttreatment assessment)

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 V66M

heart rate, blood pressure) and/or a genetic polymorphism (BDNF Val66Met) obtained from a saliva sample will be examined. --- Val66Met ---



HPO Nodes